SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radioactive 'Smart Bomb' targets Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…
Matched conditions: SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Lumara Bio Oncologics GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug HDM2020 targets tough lung cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called HDM2020 in 150 people with advanced squamous non-small cell lung cancer. The drug is designed to target a protein on cancer cells and deliver a chemotherapy agent directly to them. The main goals are to check if the drug is safe…
Matched conditions: SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cell therapy targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system atta…
Matched conditions: SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Zelluna Immunotherapy AS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC